🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Fujifilm Announces the Commercialization of Two Novel Endoscopic Imaging Technologies, CAD EYE ® and SCALE EYE ® at the Digestive Disease Week (DDW ®) 2024 Conference

Published 2024/05/16, 19:06

Lexington, MA, May 16, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, today announced the commercialization of its two novel endoscopic imaging technologies, CAD EYE ®, the company's AI detection system for endoscopic imaging which enables real-time detection of colonic mucosal lesions during colonoscopy procedures, and SCALE EYE ®, a first-of-its-kind imaging technology for measuring colonic lesions. Both technologies will be demonstrated at the 2024 Digestive Disease Week (DDW ®) annual conference and exhibition in booth 2829, held May 18-21 in Washington, DC.

Our vision has been laser focused on delivering the best possible endoscopic imaging solutions to meet our customers' growing needs. Knowing how critical it is for GI physicians to accurately visualize and measure lesions during colonoscopy, we are eager to launch CAD EYE and SCALE EYE, says Tai Fujita, vice president, Endoscopy Division, FUJIFILM Healthcare Americas Corporation. Our team looks forward to demonstrating how Fujifilm's state-of-the-art endoscopic technologies are offering outstanding levels of image clarity and performance to industry experts and physicians at the upcoming DDW.

Since receiving 510(k) clearance for CAD EYE in March, the technology has been installed at five clinical sites in the U.S., including ASCs, community hospitals, and academic medical centers.  

This system expansion from Fujifilm represents an exciting step forward at a time when quality in colonoscopy is a critical focus across the GI community, said Jason B. Samarasena, MD, gastroenterologist with UCI Health. Leveraging AI for polyp detection support with CAD EYE, along with the introduction of SCALE EYE, a novel real-time polyp measurement solution “ both seamlessly integrated with the innovative ELUXEO platform - Fujifilm is helping to address several key challenges and working alongside endoscopists to elevate quality standards in colonoscopy.

Two recognized industry leaders will present real-world application as well as clinical findings on Fujifilm's novel CAD EYE in booth #2829 at the upcoming DDW conference, including:

New Paradigm for Colonoscopy 2024: Sunday, May 19 11:30am “ 12:30 pm ET

Alessandro Repici, MD, Professor of Gastroenterology, Chairman Department of Gastroenterology, Humanitas University & Humanitas Research Hospital will present on CAD EYE colon polyp detection in practice, and how the Fujifilm ELUXEO system delivers a comprehensive set of innovative solutions for endoscopy.

CAD EYE: US Clinical Trial Data and Why It's Compelling: Monday, May 20 11:30am “ 12:30 pm ET

Sravanthi Parasa, MD, FASGE, Gastroenterology, Swedish Medical Center, Clinical Researcher in Gastroenterology & AI in Medicine will present clinical findings on CAD EYE  advances in colorectal cancer diagnosis, including 17% higher adenoma per colonoscopy (APC) compared to high-definition conventional colonoscopy without AI assistance, the ability to detect colorectal neoplastic lesions at a level comparable to that of an expert and superior to that of a beginner  1 , and more.  

To book your demonstration with Fujifilm at DDW 2024, click here.

1.    Neumann H et al. 2021. PLoS One 16(8):e0255955, PMID: 34437563.

About Fujifilm

FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm's innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse ® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm's AI initiative, REiLI ®, combines Fujifilm's rich image-processing heritage with cutting-edge innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labelling products. The company is headquartered in Lexington, Massachusetts. Click here for more information.

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm's Sustainable Value Plan 2030, click here. For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion USD at an exchange rate of 134 yen/dollar). For more information, please visit:  www.fujifilmholdings.com.

FUJIFILM, CAD EYE, SCALE EYE, ELUXEO, SYNAPSE, REILI and VALUE FROM INNOVATION are trademarks and registered trademarks of FUJIFILM Corporation and its affiliates. DDW is a registered trademark of DDW, LLC. All other trademarks are the property of their respective owners.

Marissa ConfredoFUJIFILM Holdings America Corporation914-789-8526marissa.confredo@fujifilm.com
Source: FUJIFILM Holdings America Corporation

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.